|
DCF -Bewertung von Regencell Bioscience Holdings Limited (RGC) |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Regencell Bioscience Holdings Limited (RGC) Bundle
Möchten Sie den inneren Wert von Regencell Bioscience Holdings Limited bewerten? Unser (RGC) DCF -Taschenrechner verbindet praktische Daten mit umfangreichen Anpassungsfunktionen, sodass Sie Ihre Prognosen verfeinern und fundiertere Investitionsentscheidungen treffen können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -.8 | -1.4 | -7.0 | -5.3 | -3.6 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | .0 | .6 | .8 | .7 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -.8 | -1.4 | -7.6 | -6.1 | -4.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | .4 | .1 | 16.4 | 11.6 | 8.0 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .2 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.1 | .0 | -.8 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 1.41 | 1.41 | 1.41 | 1.41 | 1.41 | 1.41 | 1.41 | 1.41 | 1.41 | 1.41 |
| EBITAT | -.8 | -1.4 | -7.4 | -5.9 | -4.3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -.9 | -1.3 | -7.6 | -5.1 | -3.8 | .2 | .0 | .0 | .0 | .0 |
| WACC, % | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| PV UFCF | ||||||||||
| SUM PV UFCF | .1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | 3 | |||||||||
| Diluted Shares Outstanding, MM | 13 | |||||||||
| Equity Value Per Share | 0.23 |
What You Will Receive
- Pre-Filled Financial Model: Regencell's actual data allows for accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates provide immediate feedback as you adjust inputs.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, enabling repeated application for in-depth forecasts.
Key Features
- Comprehensive RGC Data: Pre-filled with Regencell Bioscience Holdings Limited’s historical financials and future projections.
- Customizable Financial Inputs: Modify key metrics such as revenue growth, profit margins, WACC, tax rates, and capital expenditures.
- Interactive Valuation Model: Automatically recalculates Net Present Value (NPV) and intrinsic value based on user inputs.
- Multiple Scenario Analysis: Develop various forecast scenarios to evaluate different valuation results.
- User-Centric Interface: Intuitive, organized, and suitable for both seasoned professionals and newcomers.
How It Works
- Step 1: Download the prebuilt Excel template featuring Regencell Bioscience Holdings Limited’s (RGC) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly observe recalculated results, including Regencell’s intrinsic value.
- Step 5: Make educated investment choices or create reports based on the outputs.
Why Choose This Calculator for Regencell Bioscience Holdings Limited (RGC)?
- Designed for Experts: A specialized tool tailored for analysts, investors, and biotech consultants.
- Accurate Data: Regencell’s historical and projected financials are preloaded for precise analysis.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and other essential metrics.
- User-Friendly: Step-by-step guidance makes the process straightforward and accessible.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Regencell Bioscience Holdings Limited (RGC) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Regencell Bioscience Holdings Limited (RGC).
- Consultants: Deliver professional valuation insights on Regencell Bioscience Holdings Limited (RGC) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like Regencell Bioscience Holdings Limited (RGC) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Regencell Bioscience Holdings Limited (RGC).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Regencell Bioscience Holdings Limited (RGC) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Regencell Bioscience Holdings Limited (RGC).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.